Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,145.03 USD
-5.16 (-0.45%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1,150.00 +4.97 (0.43%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Regeneron Pharmaceuticals, Inc. [REGN]
Reports for Purchase
Showing records 121 - 140 ( 596 total )
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
NICE Backs Dupixent as Add-On Therapy Option for Severe Asthma in Patients Ages 12+; Reiterate Buy and $844 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Oh My Oh My Omicron: Does the Latest Variant Spell the End of REGEN-COV?
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Recent Developments Reaffirm Our Enthusiasm for Regeneron; Reiterate Buy Rating and $844 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
R&D Day Reveal; Alnylam-Regeneron Partner in ALS and Glaucoma; Reiterate Buy and $844 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Triumvirate of Dupixent, Eylea and REGEN-COV Drive 3Q2021 Revenue and EPS Beat; Reiterate Buy; Raise PT to $844
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Our Outlook for Regeneron?s Upcoming 3Q21 Earnings Report
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dupixent Receives Second Positive Phase 3 Results for Eosinophilic Esophagitis; Reiterate Buy, Maintain PT at $842
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dupixent Recieves Positive Phase 3 Results for Prurigo Nodularis; Reiterate Buy and Increase PT to $842
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Asthmatic Children Will Now Breathe Better After Dupixent?s FDA Label Expansion
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDA Accepts REGEN-COV BLA for Priority Review; We See No Barriers to Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Sell-Off on Bout of COVID-opia Provides Entry Point for REGN Shares; Reiterate Buy and $831 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Another Libtayo Phase 3 Win in NSCLC-EMPOWER-Lung 3 Stopped Early, Hits in 1L in Chemo Combo
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Tail Grows Longer; REGEN-COV Lands HHS Repeat Order for 1.4M Doses Totaling $2.9B; Reit Buy, Raise PT to $831
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department